Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical has announced that it will commence shipment of 12.5mg and 25mg meclizine HCl tablets immediately.
Subscribe to our email newsletter
Par marketed meclizine prior to an explosion at the facility of its active pharmaceutical ingredients (API) supplier in February 2008. Par has since qualified a new API source and received the appropriate approval of its supplemental new drug application to manufacture and market meclizine HCl utilizing its new API supplier.
Meclizine is an oral antiemetic indicated for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness.